Claims for Patent: 11,439,597

Summary for Patent: 11,439,597

Title:	Formulations of (R)-2-amino-3-phenylpropyl carbamate
Abstract:	The present invention relates to immediate release formulations of (R)-2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.
Inventor(s):	Allphin Clark Patrick, Walsh Edwin Gerard
Assignee:	Axsome Malta Ltd.
Application Number:	US17154336
Patent Claims:	2. The solid pharmaceutical formulation of claim 1 , wherein the formulation releases at least 95% of the (R)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof contained therein within a period of less than 15 minutes after administration of the formulation to a subject.3. The solid pharmaceutical formulation of claim 1 , wherein hydroxypropyl cellulose is in an amount of about 1-3% by weight of the formulation.4. The solid pharmaceutical formulation of claim 1 , wherein magnesium stearate is in an amount of about 0.1% to about 1.0% by weight of the formulation.5. The solid pharmaceutical formulation of claim 1 , wherein(R)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof is in an amount of about 90-98% by weight of the formulation;hydroxypropyl cellulose is in an amount of about 1-5% by weight of the formulation; andmagnesium stearate is in an amount of about 0.1-2% by weight of the formulation.6. The solid pharmaceutical formulation of claim 1 , wherein(R)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof is in an amount of about 90-98% by weight of the formulation;hydroxypropyl cellulose is in an amount of about 2% by weight of the formulation; andmagnesium stearate is in an amount of about 0.5% by weight of the formulation.7. The solid pharmaceutical formulation of claim 1 , wherein the (R)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof is (R)-2-amino-3-phenylpropyl carbamate hydrochloride.8. The solid pharmaceutical formulation of claim 1 , wherein the coating is present.9. The solid pharmaceutical formulation of claim 8 , wherein the coating is a color overcoat.11. The solid pharmaceutical formulation claim 10 , wherein the formulation releases at least 95% of the (R)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof contained therein within a period of less than 15 minutes after administration of the formulation to a subject.12. The solid pharmaceutical formulation of claim 10 , wherein hydroxypropyl cellulose is in an amount of about 1-3% by weight of the formulation.13. The solid pharmaceutical formulation of claim 10 , wherein magnesium stearate is in an amount of about 0% to about 1.0% by weight of the formulation.14. The solid pharmaceutical formulation of claim 10 , wherein(R)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof is in an amount of about 90-98% by weight of the formulation;hydroxypropyl cellulose is in an amount of about 1-5% by weight of the formulation; andmagnesium stearate is in an amount of about 0.1-2% by weight of the formulation.15. The solid pharmaceutical formulation of claim 10 , wherein(R)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof is in an amount of about 90-98% by weight of the formulation;hydroxypropyl cellulose is in an amount of about 2% by weight of the formulation; andmagnesium stearate is in an amount of about 0.5% by weight of the formulation.16. The solid pharmaceutical formulation of claim 10 , wherein the (R)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof is (R)-2-amino-3-phenylpropyl carbamate hydrochloride.17. The solid pharmaceutical formulation of claim 10 , wherein the coating is present.18. The solid pharmaceutical formulation of claim 10 , wherein the coating is a color overcoat.